- HMS Community Values
- Introduction to Clinical Research Training
- Medical Education
- Clinical Scholars Research Training - United Kingdom
- Vanderbilt Hall
- Financial Aid
- Office of the Registrar
- Campus Planning and Facilities
- Ombuds Office
- Committee on Microbiological Safety
- Human Resources
- The Academy
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Harvard Medical School Event Calendar
- Office of Diversity RIA Program
- The Dean's Perspective
- Department of Pathology
- Harvard Mahoney Neuroscience Institute
- OHRA Home
- Office of Research Subject Protection
- Cancer Biology & Therapeutics Program
- Celiac Program
- Department of Medicine
- HMS Information Technology
- HMS TransMed Program
- Introduction to Postgraduate American Medicine
- Office of Communications & External Relations
- Big Data In Healthcare
- Global Pediatrics Leadership Program
- Institutional Planning and Policy
- Master of Medical Sciences In Clinical Investigation
- Office of Global Education
- Portugal Clinical Scholars Research Training Program
- Safety Quality Informatics and Leadership
- South American Clinical Research Training Program | SACRT
- Southeast Asia Healthcare Leadership Program
- Training to Teacher
- Shenzhen-HMS Initiative in International Education
- Contact @HMS
- Office of Global Education
- Human Resources
- Jobs @ HMS
- Dental Medicine
- Harvard University
- Contact us
Doubling Forces Against Glioblastomas
A novel combination of two oral targeted drugs dramatically slowed the growth of glioblastoma brain tumors in mice and significantly extended the animals’ survival, report scientists at Harvard Medical School and Dana-Farber Cancer Institute.
The researchers paired two drugs that inhibit overactivity of two cell signaling pathways that drive many glioblastomas, the most lethal malignant brain tumors. Previous attempts to treat this type of glioblastoma by blocking just one of the pathways were unsuccessful. A report on the new study was posted online by Nature Medicine.
The drug combination targets a genetic abnormality found in about one-third of glioblastomas: a mutation that disables PTEN, a tumor suppressor gene. This strategy is only relevant to glioblastomas that are driven by the loss of PTEN. Other glioblastomas develop through a variety of other genetic flaws for which scientists are testing different targeted treatments.
Loss of the PTEN gene unleashes a chain reaction, with overactive molecular growth signals spurring cells into malignant growth; cells pile up to form aggressive tumors that infiltrate the brain. Scientists can’t replace the PTEN gene to restore order; instead, they use drugs to block the excessive growth signaling that flows through gene networks.
Overactivity in a signaling pathway known as PI3K is a known culprit in glioblastomas lacking the PTEN gene, and drugs are available to inhibit PI3K activity. But drugs that block PI3K alone haven’t had much success in slowing brain tumors.
Looking for another chink in glioblastomas’ defenses, the researchers, led by Rosalind Segal, HMS professor of neurobiology at Dana-Farber, found that another signaling pathway, known as sonic hedgehog or Shh, also is activated by PTEN loss and gangs up synergistically with PI3K. “You have a very strong dual gas pedal” fueling the cancer’s growth, Segal said. That explained why treating the tumors with a single inhibitor that dampens PI3K signaling but not Shh signaling hasn’t been effective for PTEN-deficient glioblastomas.
To test whether blocking both PI3K and Shh signaling simultaneously would have greater impact, the researchers tested inhibitor combinations on glioblastoma “neurospheres”—small clumps of human tumor cells grown in laboratory culture. Using several different targeted drugs, they showed that the strategy worked to slow growth in the tumor cells lacking PTEN but not in those where the tumor suppressor gene was intact.
Next, the scientists injected human glioblastoma cells into mice, where they formed rapidly growing tumors, and compared the effects of administering a dummy drug, a single drug that blocked PI3K, a single drug blocking Shh and a combination of inhibitors against PI3K and Shh. As anticipated, the two-drug combination shrank tumors and slowed their growth, and the animals lived much longer than those in the other three groups.
Segal noted that promising results in mice often fail to translate to humans, but said she’s hopeful that the new strategy may contribute to more successful treatment of glioblastomas, which resist most current treatments and have a poor survival rate.
“These are oral drugs, taken in pill form once a day, and we know they cross the blood-brain barrier and reach the tumor,” Segal said.
Based on the study’s findings, a phase 1 international clinical trial has been launched in adults with glioblastoma, said Patrick Wen, HMS professor of neurology and director of the Center for Neuro-Oncology at Dana-Farber/Brigham and Women’s Cancer Center. A similar trial for pediatric patients is scheduled to open in 2014.
The research was supported by grants from the Novartis Institute of BioMedical Research and National Institutes of Health (NIH/NCI /1P01 CA142536-01A1 and NIH/DP1 OD000839).
Adapted from a Dana-Farber Cancer Institute news release.
Stay informed via email on the latest news, research, and
media from Harvard Medical School.